The rationale/design of the Guimarães/Vizela study: A multimodal population-based cohort study to determine global cardiovascular risk and disease

Journal of Investigative Medicine

Volumn 62, Issue 5, 2014, Pages 813-820

  Cunha, Pedro Guimarães ^a,b   Cotter, Jorge ^a,b   Oliveira, Pedro ^b   Vila, Isabel ^a   Sousa, Nuno ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Arterial stiffness; Blood pressure; Cardiovascular risk; Chronic kidney disease; Cognitive impairment; Early vascular aging

Indexed keywords

ABDOMINAL OBESITY; ADULT; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; HYPERURICEMIA; INCIDENCE; KIDNEY DISEASE; MENTAL DETERIORATION; METABOLIC SYNDROME X; MORTALITY; OBESITY; PHENOTYPE; PORTUGAL; PREVALENCE; PULSE WAVE; RISK ASSESSMENT; TARGET ORGAN; TOBACCO USE; AGED; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; MALE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PORTUGAL; RISK FACTORS;

EID: 85047687285     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0000000000000069     Document Type: Article

References (86)

1. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850-2870. (Pubitemid 46018288)
2. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006;114:2871-2891. (Pubitemid 46018289)
3. O'Rourke MF, Safar ME, Dzau V. The cardiovascular continuum extended: aging effects on the aorta and microvasculature. Vasc Med. 2010;15:461-468.
4. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2095-2128.
5. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187. (Pubitemid 46924065)
6. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. (Pubitemid 36712275)
7. Reiner Z, Catapano AL, de Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818.
8. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35 (suppl 1):S64-S71.
9. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-S290.
10. Perk J, de Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33:1635-1701.
11. Santos NC, Costa PS, Cunha P, et al. Mood is a key determinant of cognitive performance in community-dwelling older adults: a cross-sectional analysis. Age (Dordr). 2013;35:1983-1993.
12. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011;124:314-323.
13. Correia M, Silva MR, Matos I, et al. Prospective community-based study of stroke in Northern Portugal: incidence and case fatality in rural and urban populations. Stroke. 2004;35:2048-2053. (Pubitemid 39129558)
14. Correia M, Silva MR, Magalhaes R, et al. Transient ischemic attacks in rural and urban northern Portugal: incidence and short-term prognosis. Stroke. 2006;37:50-55. (Pubitemid 43732047)
15. Muller-Nordhorn J, Binting S, Roll S, et al. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008;29:1316-1326. (Pubitemid 351768126)
16. Ferreira-Pinto LM, Rocha-Goncalves F, Teixeira-Pinto A. An ecological study on the geographic patterns of ischaemic heart disease in Portugal and its association with demography, economic factors and health resources distribution. BMJ Open. 2012;2. pii:e000595.
17. Macedo ME, Lima MJ, Silva AO, et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens. 2005;23:1661-1616.
18. Cortez-Dias N, Martins S, Belo A, et al. Prevalence and management of hypertension in primary care in Portugal. Insights from the VALSIM study. Rev Port Cardiol. 2009;28:499-523.
19. de Macedo ME, Lima MJ, Silva AO, et al. Prevalence, awareness, treatment and control of hypertension in Portugal. The PAP study. Rev Port Cardiol. 2007;26:21-39.
20. Clara JG, de Macedo ME, Pego M. Prevalence of isolated systolic hypertension in the population over 55 years old. Results from a national study. Rev Port Cardiol. 2007;26:11-18. (Pubitemid 46423621)
21. Figueiredo D, Azevedo A, Pereira M, et al. Definition of hypertension: the impact of number of visits for blood pressure measurement. Rev Port Cardiol. 2009;28:775-783.
22. Modesti PA, Rapi S, Bamoshmoosh M, et al. Impact of one or two visits strategy on hypertension burden estimation in HYDY, a population-based cross-sectional study: implications for healthcare resource allocation decision making. BMJ Open. 2012;0:e001062.
23. Bovet P, Gervasoni JP, Ross AG, et al. Assessing the prevalence of hypertension in populations: are we doing it right? J Hypertens. 2003;21:509-517.
24. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11-19. (Pubitemid 38293521)
25. Pereira M, Lunet N, Azevedo A, et al. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27:963-975.
26. Pereira M, Carreira H, Vales C, et al. Trends in hypertension prevalence (1990-2005) and mean blood pressure (1975-2005) in Portugal: a systematic review. Blood Pressure. 2012;21:220-226.
27. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377:568-577.
28. Leal J, Luengo-Fernandez R, Gray A, eds. European Cardiovascular Disease Statistics 2012. ed. Brussels: European Heart Network, Sophia Antipolis: European Society of Cardiology; 2012.
29. Saúde DGd. Statistic ElementsVGeneral Health Information/2008. Saúde DGd, ed. Lisbon, Portugal: Direcça?o Geral de Saúde; 2010:159.
30. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
31. Gardete-Correia L, Boavida JM, Raposo JF, et al. First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med. 2010;27:879-881.
32. Cortez-Dias N, Martins S, Belo A, et al. Prevalence, management and control of diabetes mellitus and associated risk factors in primary health care in Portugal. Rev Port Cardiol. 2010;29:509-537.
33. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-321.
34. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050-1065. (Pubitemid 37413751)
35. de Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl. 2005:S25-S29.
36. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
37. Ruilope L, Kjeldsen SE, de la Sierra A, et al. The kidney and cardiovascular risk-implications for management: a consensus statement from the European Society of Hypertension. Blood Pressure. 2007;16:72-79. (Pubitemid 47053774)
38. Vinhas J, Gardete-Correia L, Boavida JM, et al. Prevalence of chronic kidney disease and associated risk factors, and risk of end-stage renal disease: data from the PREVADIAB study. Nephron Clin Pract. 2011;119:c35-c40.
39. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
40. Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol. 2009;20:465-468.
41. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17-28.
42. Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349-2360.
43. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662-1673.
44. Polonia J, Carmona J, Mendes E, et al. Prevalence of microalbuminuria in non-diabetic hypertensive patients attended by Portuguese GPs. Rev Port Cardiol. 2007;26:637-644. (Pubitemid 47122813)
45. Costa J, Borges M, Oliveira E, et al. Incidence and prevalence of hypercholesterolemia in Portugal: a systemic review. Part II. Rev Port Cardiol. 2003;22:683-702.
46. Costa J, Borges M, Oliveira E, et al. Incidence and prevalence of hypercholesterolemia in Portugal: a systematic review. Part I. Rev Port Cardiol. 2003;22:569-577.
47. Costa J, Borges M, Oliveira E, et al. Incidence and prevalence of hypercholesterolemia in Portugal: a systematic review. Part III. Rev Port Cardiol. 2003;22:829-836.
48. Fiuza M, Cortez-Dias N, Martins S, et al. Metabolic syndrome in Portugal: prevalence and implications for cardiovascular riskVresults from the VALSIM Study. Rev Port Cardiol. 2008;27:1495-1529.
49. da Silva PM, Cardoso SM. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). Rev Port Cardiol. 2011;30:47-63.
50. Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011;377:578-586.
51. Santos AC, Lopes C, Barros H. Prevalence of metabolic syndrome in the city of Porto. Rev Port Cardiol. 2004;23:45-52.
52. Sardinha LB, Santos DA, Silva AM, et al. Prevalence of overweight, obesity, and abdominal obesity in a representative sample of Portuguese adults. PLoS One. 2012;7:e47883.
53. do Carmo I, Dos Santos O, Camolas J, et al. Overweight and obesity in Portugal: national prevalence in 2003-2005. Obes Rev. 2008;9:11-19.
54. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121:505-511.
55. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318-1327.
56. Laurent S, Cockcroft J, van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605. (Pubitemid 44627304)
57. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
58. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010;31:2338-2350.
59. Polonia J, Maldonado J, Ramos R, et al. Estimation of salt intake by urinary sodium excretion in a Portuguese adult population and its relationship to arterial stiffness. Rev Port Cardiol. 2006;25:801-817.
60. Maldonado J, Pereira T, Polonia J, et al. Arterial stiffness predicts cardiovascular outcome in a low-to-moderate cardiovascular risk population: the EDIVA (Estudo de DIstensibilidade VAscular) project. J Hypertens. 2011;29:669-675.
61. Pereira T, Maldonado J, Polonia J, et al. A statistical definition of aortic pulse wave velocity normality in a Portuguese population: a subanalysis of the EDIVA project [Portuguese]. Rev Port Cardiol. 2011;30:691-698.
62. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50:154-160. (Pubitemid 46986036)
63. Vlachopoulos C, Aznaouridis K, O'Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31:1865-1871.
64. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197-203. (Pubitemid 46986041)
65. Roman MJ, Devereux RB, Kizer JR, et al. High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study. J Am Coll Cardiol. 2009;54:1730-1734.
66. Briet M, Pierre B, Laurent S, et al. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 2012;82:388-400.
67. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005;46:200-204. (Pubitemid 40946514)
68. Nilsson PM, Boutouyrie P, Cunha P, et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31:1517-1526.
69. Nilsson PM. Early vascular aging (EVA): consequences and prevention. Vasc Health Risk Manag. 2008;4:547-552. (Pubitemid 352042403)
70. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a ''set up'' for vascular disease. Circulation. 2003;107:139-146. (Pubitemid 36070946)
71. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107:490-497. (Pubitemid 36158054)
72. Laurent S. Defining vascular aging and cardiovascular risk. J Hypertens. 2012; (suppl 30):S3-S8.
73. Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome. J Hypertens. 2008;26:1049-1057. (Pubitemid 351670493)
74. Kotsis V, Stabouli S, Karafillis I, et al. Early vascular aging and the role of central blood pressure. J Hypertens. 2011;29:1847-1853.
75. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-2713.
76. Gorelick PB,William M. Feinberg lecture: cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke. 2005;36: 875-879.
77. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364:2227-2234.
78. Inzitari D, Pracucci G, Poggesi A, et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (Leukoaraiosis and Disability) study cohort. BMJ. 2009;339:b2477.
79. Poggesi A, Pantoni L, Inzitari D, et al. 2001-2011: A decade of the LADIS (Leukoaraiosis And DISability) study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis. 2011;32:577-588.
80. Verdelho A, Madureira S, Ferro JM, et al. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry. 2007;78:1325-1330. (Pubitemid 350221411)
81. Nunes B, Silva RD, Cruz VT, et al. Prevalence and pattern of cognitive impairment in rural and urban populations from Northern Portugal. BMC Neurol. 2010;10:42.
82. Maillard P, Seshadri S, Beiser A, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol. 2012;11:1039-1047.
83. Waldstein SR, Rice SC, Thayer JF, et al. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008;51:99-104. (Pubitemid 350307110)
84. Scuteri A, Tesauro M, Appolloni S, et al. Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. J Hypertens. 2007;25:1035-1040. (Pubitemid 46573123)
85. Pase MP, Herbert A, Grima NA, et al. Arterial stiffness as a cause of cognitive decline and dementia: a systematic review and meta-analysis. Intern Med J. 2012;42:808-815.
86. Henskens LH, Kroon AA, van Oostenbrugge RJ, et al. Increased aortic pulse wave velocity is associated with silent cerebral small-vessel disease in hypertensive patients. Hypertension. 2008;52:1120-1126.